West Pharmaceutical Services Beats Q3 2026 Estimates by 21%
As seen on the 24/7 Wall St. homepage on October 29, 2026.
Management raised full-year EPS guidance to $9.38 to $9.48 as high-value product components grew 20.3% organically on GLP-1 and biologics demand.
Continue ReadingShow less
West Pharmaceutical Services posted adjusted earnings per share of $2.66 for the third quarter of 2026, beating expectations for the fifth straight quarter.
Revenue rose 8.7% year over year, led by High-Value Product Components, which now account for 53% of total sales. The mix keeps shifting toward the highest-margin, fastest-growing lines.
Adjusted operating margin expanded 420 basis points to 25.3%, as demand from GLP-1 and non-GLP-1 biologics customers drove volume and pricing leverage. Asia Pacific organic sales rose 41.9%.
Sponsored
Management raised full-year adjusted EPS guidance to $9.38 to $9.48 and lifted the net sales outlook. The company also announced an 18% dividend increase to $0.26 per share quarterly, declared on October 19, 2026.
GAAP diluted EPS of $3.02 exceeded the adjusted figure on a $55.7 million pre-tax gain from the SmartDose 3.5mL On-Body Delivery System divestiture to AbbVie. That sale trims future revenue, with Q4 organic growth guided to 6% to 7%.
Mentioned: WST